Mixed trend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Mar 28 · inside the Ichimoku cloud · RSI 0 (oversold) · MACD above its signal · at its 52-week high
None of the 29 investors followed here reported a position in MYMX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MYMX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for MYMX.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | 0.0 | 0.0 | -70.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −70.0% |
| 2024 | -91.9 | -96.2 | 0.0 | 0.0 | -90.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −100.0% |
| 2023 | -11.9 | 17.3 | -3.2 | -77.7 | 29.9 | 157.5 | -33.0 | -90.7 | 21.4 | -58.8 | 228.6 | -30.4 | −94.7% |
| 2022 | 0.0 | 6.1 | 136.6 | -33.3 | 8.7 | -8.5 | -12.6 | -2.5 | -1.9 | -13.3 | -19.6 | -6.3 | −9.1% |
| 2021 | 13.9 | 21.7 | 14.2 | -15.5 | -2.5 | -29.1 | 9.5 | -11.3 | -7.1 | -39.3 | -12.7 | -5.4 | −58.2% |
| 2020 | -18.5 | 1.5 | 9.1 | -8.3 | 45.5 | -6.9 | 2.2 | 0.8 | 8.0 | 2.4 | 47.2 | 5.5 | +98.0% |
| 2019 | -19.1 | -15.1 | -31.1 | 53.0 | 5.4 | -12.6 | 28.8 | -6.0 | -7.8 | 2.3 | -6.3 | 6.7 | −23.9% |
| 2018 | 40.2 | -5.4 | -0.4 | 107.9 | -31.0 | 27.5 | 5.9 | -20.4 | 15.6 | 20.7 | 8.3 | -19.4 | +148.2% |
| 2017 | 12.4 | 0.3 | 8.4 | -12.0 | 43.2 | -18.4 | -2.7 | 156.0 | 9.2 | 0.1 | -64.2 | -15.7 | +3.2% |
| 2016 | 31.7 | -19.8 | -15.8 | 6.3 | 5.9 | -11.1 | 0.0 | -15.6 | 8.1 | -17.8 | -16.7 | 104.6 | +13.7% |
| 2015 | -20.0 | 12.5 | 2.2 | 2.2 | -6.4 | -7.7 | -1.5 | -5.0 | -36.8 | 17.5 | -14.2 | 48.8 | −28.0% |
| 2014 | 400.0 | -0.5 | -7.7 | -9.3 | -22.0 | -23.1 | 23.3 | -32.4 | 34.4 | -7.7 | -22.9 | 4.6 | +108.3% |
| 2013 | -26.8 | 66.0 | -20.5 | 29.0 | -35.0 | -23.1 | -20.0 | -23.8 | 23.0 | 46.7 | -31.8 | -20.0 | −62.6% |
| 2012 | 15.4 | 18.3 | 181.7 | -44.0 | -1.8 | -27.3 | 0.0 | -5.0 | 0.0 | -2.6 | -42.7 | 51.4 | +23.5% |
| 2011 | -28.6 | 29.2 | -3.2 | -6.7 | -7.1 | -3.8 | -28.0 | -44.4 | 10.0 | -16.4 | -39.1 | -7.1 | −84.5% |
| 2010 | -3.4 | 4.3 | 8.3 | 8.5 | -18.4 | 39.1 | -12.5 | 7.1 | -10.0 | -11.1 | 8.3 | 29.2 | +41.2% |
| 2009 | 0.0 | 0.0 | 9.8 | 0.0 | 0.0 | 0.0 | -26.0 | 7.7 | -3.6 | 3.7 | -7.1 | -8.5 | −25.6% |
| 2008 | 69.2 | 9.1 | 4.2 | -12.0 | 2.3 | -11.1 | 0.0 | 57.5 | 4.8 | -45.5 | -11.1 | 0.0 | +23.1% |
| 2007 | 34.6 | -31.4 | 650.0 | -41.7 | -9.5 | 15.8 | 18.2 | -23.1 | 10.0 | 18.2 | 15.4 | -13.3 | +400.0% |
No analyst coverage for this instrument.
Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, and malaria. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; and national institutes of health. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.
No recent headlines.